It is expected that pirtobrutinib, when used as first-line BTK inhibitor treatment in relapsed MCL, will be more effective than the covalent BTK inhibitors (ibrutinib, acalabrutinib, or zanubrutinib) [147,148]. The gene discussed is BTK; the disease is mantle cell lymphoma.